Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and kainate-type ionotropic glutamate receptors (AMPA/kainate receptors)

AMPA and kainate receptors are subtypes of ionotropic glutamate receptors that mediate the majority of fast excitatory neurotransmission in the mammalian central nervous system. AMPA receptors (AMPARs) are primarily responsible for the initial postsynaptic depolarization, while kainate receptors (KARs) play specialized roles in both presynaptic and postsynaptic signaling and the regulation of synaptic excitability (Source: UniProt, P42261; PubMed, PMID: 21436830). These receptors are tetrameric assemblies of subunits (GluA1-4 for AMPA and GluK1-5 for kainate) that form a cation-selective pore which opens upon glutamate binding. Dysfunction of these receptors is linked to various neurological and psychiatric disorders, including epilepsy, where overactivation leads to seizure activity, and neurodegenerative diseases like ALS and Alzheimer's, where excitotoxicity contributes to neuronal death (Source: NIH, PMC3558538). Pharmacological intervention includes the use of antagonists like perampanel for seizure control and the investigation of positive allosteric modulators to treat cognitive deficits. Because of their ubiquitous expression, targeting these receptors requires a balance between therapeutic efficacy and avoiding widespread central nervous system side effects such as sedation or motor impairment.

Other names

Non-NMDA glutamate receptorsAMPA receptorsKainate receptorsAMPARKARQuisqualate receptorsGlutamate ionotropic receptor AMPA typeGlutamate ionotropic receptor kainate type

Drugs targeting these receptors typically act as non-competitive or competitive antagonists to reduce excitatory signaling, or as positive allosteric modulators (AMPAkines) to enhance cognitive function and synaptic plasticity (Source: PubMed, PMID: 24411251; StatPearls, NBK542240).